Braveheart Bio is considered undervalued as a late-stage player in hypertrophic cardiomyopathy (HCM) treatment, with two fully funded Phase 3 clinical trials underway. The company holds $527 million in cash, supporting operations through 2029 and enabling completion of its LIONHEART-HCM and NOBLEHEART-HCM trials. Early Phase 2 data show promising safety and efficacy, with rapid, reversible effects and minimal impact on heart function, positioning Braveheart favorably against competitors. Despite trading near its IPO price, the stock offers significant growth potential due to its innovative approach and untapped market opportunities in non-obstructive HCM.
Braveheart Bio's developments in hypertrophic cardiomyopathy treatment provide context for health sector activity on Pluang. As of Oct 20, 2026 19:43 WIB, out of 150 priced Health-sector US stocks tradable on Pluang, 89 rose and 58 fell. Notable movers include TXG at USD 68.50 with a 1-day change of -1.99% and 100% sell order activity, CRSP at USD 49.05 with a 1-day change of -1.98% and 83% buy order activity, and NVAX at USD 10.62 with a 1-day change of -1.89% and 64% buy order activity. The most notable figure is TXG's 100% sell order activity on Pluang.
Hershey is preparing to announce its Q3 earnings on October 29, with analysts forecasting earnings per share (EPS) of $2.12, a 63% increase from last year, and revenue of $3.25 billion, up 2.3%. The company has shown strong recent performance, with Q...
3M reported strong Q3 2026 earnings with adjusted EPS of $2.50, beating estimates of $2.38, and GAAP profit rising to $1.37 billion from $834 million a year earlier. Sales reached $6.6 billion, slightly below estimates, but showed 3.3% organic growth...
Alaska Air Group is set to report Q3 2026 earnings with analysts expecting a 66.7% drop in earnings per share to $0.35, despite a 14.5% increase in revenue to $4.31 billion driven by strong travel demand. Passenger revenue is forecast to rise 10.2%, ...
Baba, an applied AI company focused on modernizing Medicare and Medicaid care, has raised $40 million in a Series A funding round led by FirstMark Capital, with participation from CVS Health Ventures and others. The funding will help Baba expand its ...
Richard Campbell-Breeden, a seasoned investment banker with 37 years of experience including 27 years at Goldman Sachs, has joined SEDA Experts LLC as Managing Director. His expertise in mergers and acquisitions, corporate finance, and governance wil...
